Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Determine the Ability of Metamucil to Reduce Fasting Blood Glucose and HbA1c Levels in Type II NIDDM

NCT01582282 is registered in ClinicalTrials.gov with Procter and Gamble as lead sponsor.

NCT NCT01582282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01582282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Determine the Ability of Metamucil to Reduce Fasting Blood Glucose and HbA1c Levels in Type II NIDDM
Lead sponsor
Procter and Gamble
Phase
Phase 4
Overall status
Terminated
Start date
May 31, 1988
Completion date
January 31, 1990
Enrollment
37 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-insulin-dependent diabetes mellitus